Masato Furuhashi

Dr. Masato Furuhashi

Sapporo Mediacl University
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2006 in Science
Verified
Journal Article
Closed access
PDF file
UOUmut ÖzCan
Umut ÖzCan
EYErkan Yilmaz
Erkan Yilmaz
LOLale ÖzCan
Lale ÖzCan
MFMasato Furuhashi
Masato Furuhashi
EVEric Vaillancourt
Eric Vaillancourt
GHGökHan S. Hotamisligil
GökHan S. Hotamisligil
Endoplasmic reticulum (ER) stress is a key link between obesity, insulin resistance, and type 2 diabetes. Here, we provide evidence that this mechanistic link can be exploited for therapeutic purposes with orally active chemical chaperones. 4-Phenyl butyric acid and taurine-conjugated ursodeoxycholic acid alleviated ER stress in cells and whole animals. Treatment of obese and diabetic mice with these compounds resulted in normalization of hyperglycemia, restoration of systemic insulin sensitivity, resolution of fatty liver disease, and enhancement of insulin action in liver, muscle, and adipose tissues. Our results demonstrate that chemical chaperones enhance the adaptive capacity of the ER and act as potent antidiabetic modalities with potential application in the treatment of type 2 diabetes.

1 June 2008 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
MFMasato Furuhashi
Masato Furuhashi
GHGökhan S. Hotamisligil
Gökhan S. Hotamisligil

6 June 2007 in Nature
Verified
Journal Article
Closed access
PDF file
MFMasato Furuhashi
Masato Furuhashi
GTGürol Tuncman
Gürol Tuncman
CGCem Z. Görgün
Cem Z. Görgün
LMLiza Makowski
Liza Makowski
GAGenichi Atsumi
Genichi Atsumi
GHGökhan S. Hotamisligil
Gökhan S. Hotamisligil

1 February 2010 in Cell
Verified
Journal Article
Closed access
TNTakahisa Nakamura
Takahisa Nakamura
MFMasato Furuhashi
Masato Furuhashi
PLPing Li
Ping Li
HCHaiming Cao
Haiming Cao
GTGurol Tuncman
Gurol Tuncman
GHGökhan S. Hotamisligil
Gökhan S. Hotamisligil

1 February 2005 in Cell Metabolism
Verified
Journal Article
Closed access
KMKazuhisa Maeda
Kazuhisa Maeda
HCHaiming Cao
Haiming Cao
KKKeita Kono
Keita Kono
CGCem Z. Gorgun
Cem Z. Gorgun
MFMasato Furuhashi
Masato Furuhashi
GHGökhan S. Hotamisligil
Gökhan S. Hotamisligil

1 January 2014 in Clinical Medicine Insights: Cardiology
Verified
Journal Article
Open access
MFMasato Furuhashi
Masato Furuhashi
SSShigeyuki Saitoh
Shigeyuki Saitoh
KSKazuaki Shimamoto
Kazuaki Shimamoto
TMTetsuji Miura
Tetsuji Miura
Over the past decade, evidences of an integration of metabolic and inflammatory pathways, referred to as metaflammation in several aspects of metabolic syndrome, have been accumulating. Fatty acid-binding protein 4 (FABP4), also known as adipocyte FABP (A-FABP) or aP2, is mainly expressed in adipocytes and macrophages and plays an important role in the development of insulin resistance and atherosclerosis in relation to metaflammation. Despite lack of a typical secretory signal peptide, FABP4 has been shown to be released from adipocytes in a non-classical pathway associated with lipolysis, possibly acting as an adipokine. Elevation of circulating FABP4 levels is associated with obesity, insulin resistance, diabetes mellitus, hypertension, cardiac dysfunction, atherosclerosis, and cardiovascular events. Furthermore, ectopic expression and function of FABP4 in several types of cells and tissues have been recently demonstrated. Here, we discuss both the significant role of FABP4 in pathophysiological insights and its usefulness as a biomarker of metabolic and cardiovascular diseases.